26 aktiviteter 2016 med en totalsumma av SEK 160 m, summerat på
EDCTP2: European & Dev. Countries Clinical Trials Partnership 2015 - 2019 - EDCTP support 2015-2019 SEK 37 500 000

Medical Research

Beskrivning

Support to European and Developing Countries Clinical Trials Partnership to accelerate development of new or improved druugs , vaccines, microbicides and diagnostics against HIV/AIDS; TB and malaria. Support provided since 2004. A new expanded programme is planned within Horizon2020 which will be called EDCTP2.

Aktivitetslängd

Genomförandekanal

Bilateral

Ansvarig myndighet

Sida, Styrelsen för internationellt utvecklingssamarbete

Aktivitets-ID

SE-0-SE-6-5410003901-GGG-12182

WHO Research support 2016-2019 - TDR SEK 33 800 000

Medical Research

Beskrivning

The proposed intervention is programme support for the period 2016 - 2019 to three research programmes hosted by the World Health Organisation (WHO): i) Alliance for Health Policy and Systems Research, AHPSR or "the Alliance"; ii) The UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction, HRP; and iii) The UNICEF-UNDP-World Bank-WHO Special Programme for Research and Training in Tropical Diseases, TDR. The proposed support is an extension of the ongoing Agreement 2016-2017. The reason for not preparing a new agreement is that the framework agreement between Sweden/Sida and WHO lasts until 2019. The total contribution 2016-2019 is 407,2 million SEK, including 199 million SEK for the biennium 2018 - 2019. The Sida support is mainly disbursed as programme support and is therefore of particular importance to the programmes as this enables them to develop their programmes to address emerging research needs and types of support. The share of undesignated support of the total budget from all funders to the programmes were for AHPSR 78% (2015), for HRP 60% (2014) and for TDR 81% (2014). Sida's contribution during the proposed agreement period is estimated to 23% of AHPSR's overall budget, approx. 11% of the HRP's ditto, respectively 27% of TDR's ditto. Sida has extensive experience, since the mid-1970s of support to WHO for research carried out either by special research programmes or as separate research projects. Experience shows that the WHO has the ability to engage leading researchers for poverty related health issues and that the stand-alone research programmes are able to adapt to changes in the research environment and take leading role in the global research agenda. Experience has also shown that the research results produced in the programs are spread globally as a result of the WHO normative mandate. The overall assessment is that the three programmes over time have proven results in line with targets. For the biennium 2016-2017 some of the results reported are summarized below: Selected results HRP 2016-2017: 1) HRP developed new updated recommendations on the use of contraceptives and fertility care asssesment guide that was piloted in Sudan and Zambia. 2) HRP concluded a study showing that the contraceptive implant (ENG implant), currently approved for up to three years of use, can be effective for up to five years. The extended use period of the ENG implant can improve protection from inadvertent pregnancy for users and reduce costs and save resources for health systems. 3) HRP supported the development of a new tool for a standardized system for the classification of dead born infants and neonatal deaths. Pilot collection was completed for Nigeria and Uganda. 4) HRP developed a new guide: Pregnancy management in conjunction with Zika virus infection that recommends measures to prevent and manage Zika virus infection. 5) Inititated randomized control trial to determine best pain control medicament for first trimester medical abortion in Nepal, Vietnam and South Africa 6) In 2017 HRP launched the first global database on abortion law, politics, health Standards and Guidelines with data from 197 countries, including 213 jurisdictions. Selected results from the AHPSR 2016: 1) The launch of the first social awards for health systems research, together with Health Systems Global (HSG), which acknowledges the contributions of researchers and decision makers to the HPSR area and evidence-based policy making. 2) Alliance's fourth flagship report "Open mindset: Participatory leadership for health" was launched 3) Training Tools Launched by AHPSR in 2016: The HSPR Database, Online Courses on System Thinking in Public Health, and the establishment of the Global Evidence Synthesis (GESI) initiative. 4) Launch of Implementation Research Study on Electrification of Health Facilities (with PAHO) Selected results fro

Aktivitetslängd

Genomförandekanal

Bilateral

Ansvarig myndighet

Sida, Styrelsen för internationellt utvecklingssamarbete

Aktivitets-ID

SE-0-SE-6-5410017003-GGG-12182

WHO Research support 2016-2019 - HRP SEK 22 100 000

Medical Research

Beskrivning

The proposed intervention is programme support for the period 2016 - 2019 to three research programmes hosted by the World Health Organisation (WHO): i) Alliance for Health Policy and Systems Research, AHPSR or "the Alliance"; ii) The UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction, HRP; and iii) The UNICEF-UNDP-World Bank-WHO Special Programme for Research and Training in Tropical Diseases, TDR. The proposed support is an extension of the ongoing Agreement 2016-2017. The reason for not preparing a new agreement is that the framework agreement between Sweden/Sida and WHO lasts until 2019. The total contribution 2016-2019 is 407,2 million SEK, including 199 million SEK for the biennium 2018 - 2019. The Sida support is mainly disbursed as programme support and is therefore of particular importance to the programmes as this enables them to develop their programmes to address emerging research needs and types of support. The share of undesignated support of the total budget from all funders to the programmes were for AHPSR 78% (2015), for HRP 60% (2014) and for TDR 81% (2014). Sida's contribution during the proposed agreement period is estimated to 23% of AHPSR's overall budget, approx. 11% of the HRP's ditto, respectively 27% of TDR's ditto. Sida has extensive experience, since the mid-1970s of support to WHO for research carried out either by special research programmes or as separate research projects. Experience shows that the WHO has the ability to engage leading researchers for poverty related health issues and that the stand-alone research programmes are able to adapt to changes in the research environment and take leading role in the global research agenda. Experience has also shown that the research results produced in the programs are spread globally as a result of the WHO normative mandate. The overall assessment is that the three programmes over time have proven results in line with targets. For the biennium 2016-2017 some of the results reported are summarized below: Selected results HRP 2016-2017: 1) HRP developed new updated recommendations on the use of contraceptives and fertility care asssesment guide that was piloted in Sudan and Zambia. 2) HRP concluded a study showing that the contraceptive implant (ENG implant), currently approved for up to three years of use, can be effective for up to five years. The extended use period of the ENG implant can improve protection from inadvertent pregnancy for users and reduce costs and save resources for health systems. 3) HRP supported the development of a new tool for a standardized system for the classification of dead born infants and neonatal deaths. Pilot collection was completed for Nigeria and Uganda. 4) HRP developed a new guide: Pregnancy management in conjunction with Zika virus infection that recommends measures to prevent and manage Zika virus infection. 5) Inititated randomized control trial to determine best pain control medicament for first trimester medical abortion in Nepal, Vietnam and South Africa 6) In 2017 HRP launched the first global database on abortion law, politics, health Standards and Guidelines with data from 197 countries, including 213 jurisdictions. Selected results from the AHPSR 2016: 1) The launch of the first social awards for health systems research, together with Health Systems Global (HSG), which acknowledges the contributions of researchers and decision makers to the HPSR area and evidence-based policy making. 2) Alliance's fourth flagship report "Open mindset: Participatory leadership for health" was launched 3) Training Tools Launched by AHPSR in 2016: The HSPR Database, Online Courses on System Thinking in Public Health, and the establishment of the Global Evidence Synthesis (GESI) initiative. 4) Launch of Implementation Research Study on Electrification of Health Facilities (with PAHO) Selected results fro

Aktivitetslängd

Genomförandekanal

Bilateral

Ansvarig myndighet

Sida, Styrelsen för internationellt utvecklingssamarbete

Aktivitets-ID

SE-0-SE-6-5410017002-GGG-12182

WHO Research support 2016-2019 - AHPSR SEK 20 200 000

Medical Research

Beskrivning

The proposed intervention is programme support for the period 2016 - 2019 to three research programmes hosted by the World Health Organisation (WHO): i) Alliance for Health Policy and Systems Research, AHPSR or "the Alliance"; ii) The UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction, HRP; and iii) The UNICEF-UNDP-World Bank-WHO Special Programme for Research and Training in Tropical Diseases, TDR. The proposed support is an extension of the ongoing Agreement 2016-2017. The reason for not preparing a new agreement is that the framework agreement between Sweden/Sida and WHO lasts until 2019. The total contribution 2016-2019 is 407,2 million SEK, including 199 million SEK for the biennium 2018 - 2019. The Sida support is mainly disbursed as programme support and is therefore of particular importance to the programmes as this enables them to develop their programmes to address emerging research needs and types of support. The share of undesignated support of the total budget from all funders to the programmes were for AHPSR 78% (2015), for HRP 60% (2014) and for TDR 81% (2014). Sida's contribution during the proposed agreement period is estimated to 23% of AHPSR's overall budget, approx. 11% of the HRP's ditto, respectively 27% of TDR's ditto. Sida has extensive experience, since the mid-1970s of support to WHO for research carried out either by special research programmes or as separate research projects. Experience shows that the WHO has the ability to engage leading researchers for poverty related health issues and that the stand-alone research programmes are able to adapt to changes in the research environment and take leading role in the global research agenda. Experience has also shown that the research results produced in the programs are spread globally as a result of the WHO normative mandate. The overall assessment is that the three programmes over time have proven results in line with targets. For the biennium 2016-2017 some of the results reported are summarized below: Selected results HRP 2016-2017: 1) HRP developed new updated recommendations on the use of contraceptives and fertility care asssesment guide that was piloted in Sudan and Zambia. 2) HRP concluded a study showing that the contraceptive implant (ENG implant), currently approved for up to three years of use, can be effective for up to five years. The extended use period of the ENG implant can improve protection from inadvertent pregnancy for users and reduce costs and save resources for health systems. 3) HRP supported the development of a new tool for a standardized system for the classification of dead born infants and neonatal deaths. Pilot collection was completed for Nigeria and Uganda. 4) HRP developed a new guide: Pregnancy management in conjunction with Zika virus infection that recommends measures to prevent and manage Zika virus infection. 5) Inititated randomized control trial to determine best pain control medicament for first trimester medical abortion in Nepal, Vietnam and South Africa 6) In 2017 HRP launched the first global database on abortion law, politics, health Standards and Guidelines with data from 197 countries, including 213 jurisdictions. Selected results from the AHPSR 2016: 1) The launch of the first social awards for health systems research, together with Health Systems Global (HSG), which acknowledges the contributions of researchers and decision makers to the HPSR area and evidence-based policy making. 2) Alliance's fourth flagship report "Open mindset: Participatory leadership for health" was launched 3) Training Tools Launched by AHPSR in 2016: The HSPR Database, Online Courses on System Thinking in Public Health, and the establishment of the Global Evidence Synthesis (GESI) initiative. 4) Launch of Implementation Research Study on Electrification of Health Facilities (with PAHO) Selected results fro

Aktivitetslängd

Genomförandekanal

Bilateral

Ansvarig myndighet

Sida, Styrelsen för internationellt utvecklingssamarbete

Aktivitets-ID

SE-0-SE-6-5410017001-GGG-12182

INDEPTH network 2013-2017 - INDEPTH 2013-2016 SEK 10 000 000

Medical Research

Beskrivning

Support to the International Network for the Demographic Evaluation of Populations and their Health (INDEPTH, an Africa, asian and Latin American network of demographic suites to provide better, empirical understanding of health and social issues and to apply this understanding to alleviate severe health and social changes.

Aktivitetslängd

Genomförandekanal

Bilateral, core contributions to NGOs and other private bodies / PPPs

Ansvarig myndighet

Sida, Styrelsen för internationellt utvecklingssamarbete

Aktivitets-ID

SE-0-SE-6-5410004001-GGG-12182

WABA IBFAN Breastfeeding Network 2014-2017 - Support to WABA 2014-17 SEK 10 000 000

Basic nutrition

Beskrivning

The project is implemented by a consortium composed of 3 regional IBFAN offices, the Global liason office for IBFAN (GIFA) and WABA and it works towards accelerating MDG4 and 5. It is based on a human rights and gender equality princpiles and works to protect, promote and support optimal breasfeeding in order to improve the survival, health and development of children and women around the world.

Aktivitetslängd

Genomförandekanal

Bilateral

Ansvarig myndighet

Sida, Styrelsen för internationellt utvecklingssamarbete

Aktivitets-ID

SE-0-SE-6-6105012701-GGG-12240

ReAct 2015-2018 SEK 5 000 000

Infectious disease control

Beskrivning

Continued core support to the network ReAct working to advocate for improved antiobiotic resistance preparedness globally with particular focus on Africa, Asia and Latinamerica.

Aktivitetslängd

Genomförandekanal

Bilateral, core contributions to NGOs and other private bodies / PPPs

Ansvarig myndighet

Sida, Styrelsen för internationellt utvecklingssamarbete

Aktivitets-ID

SE-0-SE-6-6105013701-GGG-12250

Icddr,b research 2016-2020 - Icddr,b funding research SEK 5 000 000

Medical Research

Beskrivning

The International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) is an international health research institution located in Dhaka, dedicated to addressing the health challenges that disproportionately affect people living in poverty in Bangladesh and other low- and middle-income countries. Sida has supported icddr,b since 1981, and the institute has evolved considerably over time. The institute is today a centre of excellence producing research of global relevance, such as child and maternal health, including reproductive health. Icddr,b provides unique opportunities to address health challenges in low-income settings through low-cost, practical, lifesaving solutions. The track record includes the oral rehydration solution (ORS), zinc for diarrhoea treatment and tetanus vaccines for newborns, which have saved and continue to save millions of lives worldwide. icddr,b has the capacity to undertake a full spectrum of research spanning population-based studies and demographic surveillance, large-scale clinical trials, hospital-based clinical studies, and laboratory research. icddr,b has recently had some turbulent years with concerns of both organizational nature and regarding research sustainability, especially with regards to the regrowth of researchers at the senior level. These challenges are being addressed in different ways and the institute is currently at a transitional stage. icddr,b’s Strategic Plan 2015-2018 reinforces icddr,b’s legacy of focusing not just on discovery, but also on strengthening the organisation’s ability to shape policy at the national, regional and global level, as well as advocating for the use of highly effective products and evidence-based discoveries. icddr,b reinforces these efforts through publishing and South-South collaboration, training and capacity-building, and continues to build a cadre of public health experts and capacities for low- and middle-income countries. In addition, strategic national, regional and global partnerships tap into the complementary assets of other organisations—academic, scientific, NGOs and private sector—to maximise the influence and reach of icddr,b’s work. There are five key areas in which icddr,b has a strong track record and expertise (points 1-5 below) and two which are highly relevant to Bangladesh and where icddr,b would like to develop greater expertise (points 6-7 below): 1 Reduce maternal and neonatal mortality 2 Prevent and treat maternal and childhood malnutrition 3 Control enteric and respiratory infections 4 Detect and control emerging and re-emerging infectious diseases 5 Achieve universal health coverage 6 Non Communicable Diseases 7 Climate Change The Strategic Plan has identified the need for regrowth of the scientific base, and aim to invest in the capacity building of junior and mid-level scientists through mentoring, training, travel and exchange opportunities. This will increase the overall capacity of the institution, create a cadre of researchers with leadership potential and ensure a new generation of scientist have a strong knowledge and skill set. A new phase of research cooperation support to icddr,b is proposed for the period July 2016 - December 2020. The research funding is proposed to be used to fund research and capacity building targeting junior and mid-level scientists in line with icddr,b’s Strategic Plan. Although icddr,b is successful in attracting financing, the Swedish research support has the added value to provide support in line with the institution’s own strategic priorities including the continued capacity development of its staff. The proposal is to ensure the smooth transition from an older to a younger generation of scientists and addressing the research priorities identified in the Strategic Plan. In addition to the capacity building there is support to the finalisation of the establishment of a genomics facility, which was initiated in 2015. This facility forms the basis for innova

Aktivitetslängd

Genomförandekanal

Bilateral

Ansvarig myndighet

Sida, Styrelsen för internationellt utvecklingssamarbete

Aktivitets-ID

SE-0-SE-6-5410008901-GGG-12182

ITP 300 SRHR International Training Program Sexual & Reproductive Health & Right - ITP 300 SRHR 2017 A (B1) AVSLUTAD SEK 1 977 396

Health personnel development

Beskrivning

International Training Programme (ITP): "Sexual and Reproductive Health and Rights"

Aktivitetslängd

Genomförandekanal

Bilateral

Ansvarig myndighet

Sida, Styrelsen för internationellt utvecklingssamarbete

Aktivitets-ID

SE-0-SE-6-5402001207-GGG-12281

ITP 300 SRHR International Training Program Sexual & Reproductive Health & Right - ITP 300 SRHR 2016 C (B2) AVSLUTAD SEK 1 977 396

Health personnel development

Beskrivning

International Training Programme (ITP): "Sexual and Reproductive Health and Rights"

Aktivitetslängd

Genomförandekanal

Bilateral

Ansvarig myndighet

Sida, Styrelsen för internationellt utvecklingssamarbete

Aktivitets-ID

SE-0-SE-6-5402001206-GGG-12281

ITP 300 SRHR International Training Program Sexual & Reproductive Health & Right - ITP 300 SRHR 2016 B (B1) AVSLUTAD SEK 1 977 396

Health personnel development

Beskrivning

International Training Programme (ITP): "Sexual and Reproductive Health and Rights"

Aktivitetslängd

Genomförandekanal

Bilateral

Ansvarig myndighet

Sida, Styrelsen för internationellt utvecklingssamarbete

Aktivitets-ID

SE-0-SE-6-5402001205-GGG-12281

ITP 300 SRHR International Training Program Sexual & Reproductive Health & Right - ITP 300 SRHR 2015 B (B1)AVSLUTAD SEK 1 613 259

Health personnel development

Beskrivning

International Training Programme (ITP): "Sexual and Reproductive Health and Rights"

Aktivitetslängd

Genomförandekanal

Bilateral

Ansvarig myndighet

Sida, Styrelsen för internationellt utvecklingssamarbete

Aktivitets-ID

SE-0-SE-6-5402001203-GGG-12281

ITP 300 SRHR International Training Program Sexual & Reproductive Health & Right - ITP 300 SRHR 2016 A (B1) SEK 1 598 938

Health personnel development

Beskrivning

International Training Programme (ITP): "Sexual and Reproductive Health and Rights"

Aktivitetslängd

Genomförandekanal

Bilateral

Ansvarig myndighet

Sida, Styrelsen för internationellt utvecklingssamarbete

Aktivitets-ID

SE-0-SE-6-5402001204-GGG-12281

JPO WHO 2016 Manila Antimicrobial Resistance KK - JPO WHO 2016 Manila Antimicrobial Resistance KK AVSLUTAD SEK 1 490 823

Health policy and administrative management

Beskrivning

Sweden is committed to contribute to the implementation of Agenda 2030 in developing countries by providing human resources to work with and through the diverse mandates of UN agencies, funds and programmes, as well as the World bank. For this purpose, Sweden closely collaborates with the UN development, humanitarian and peacekeeping pillars with placements around the world.

Aktivitetslängd

Genomförandekanal

Bilateral

Ansvarig myndighet

Sida, Styrelsen för internationellt utvecklingssamarbete

Aktivitets-ID

SE-0-SE-6-5412020601-GGG-12110

Secondments to WHO middle and senior level - WHO KG SEK 1 281 653

Health policy and administrative management

Beskrivning

Secondments at middle and senior level to WHO within the broader secondment programme. This support to UN Women is planned to include 2 secondments starting 2014 and 2 starting in 2015. Average cost per secondment per year is 1,5 MSEK.

Aktivitetslängd

Genomförandekanal

Bilateral

Ansvarig myndighet

Sida, Styrelsen för internationellt utvecklingssamarbete

Aktivitets-ID

SE-0-SE-6-6104000601-GGG-12110

Treatment of incomplete second trimester abortion with misoprostol versus manual vacuum aspiration (MVA) – a randomised controlled non-inferiority tr SEK 1 085 000

Medical Research

Beskrivning

The overall aim of this project is to increase access to safe and comprehensive managmenet of second trimester incomplete abortion (referred to as “Post Abortion Care (PAC)) at district health care level in Uganda. Complications from spontaneous and unsafely induced abortions add significantly to maternal mortality and morbidity. The problem is most pronounced in the 2nd trimester of pregnancy. In low resource settings including Uganda where abortion is restrictive and often self-induced, it is imperative to provide PAC. PAC services include treatment of abortion complications such as incomplete abortion and infection and provision of contraception if required. To date, there is no established medical regimen for second trimester PAC and the recommended method is surgical manual vacuum aspiration (MVA) despite that equipment, and training is frequently lacking. Unsafe and outdated methods such as sharp curettage are frequently used. If available a medical method would incerase access to safe PAC. Therefore we propose to study the efficacy, safety and acceptability of misoprostol treatment versus MVA in a randomised controlled non-inferiority trial (RCT) including 1030 women seeking treatment for incomplete second trimester spontaneous or induced abortion at six District Health Centres in central Uganda. Primary outcome is the efficacy of the treatment to expel the retained tissue without need for additional surgical intervention. Secondary outcomes will include the safety, and acceptability of PAC provision by treatment group (MVA and misoprostol) and contraceptive uptake. All health care providers (doctors and midwives (contraceptive counselling)) providing PAC will be trained according to standardized PAC training modules. The WHO recommended misoprostol regimen for second trimester induced abortion will be used for PAC: 400mcg sublingual every 3 hours up to 5 doses Inclusion criteria: Bleeding and contractions during pregnancy. Exclusions criteria: Women < 15 years old, known allergy to misoprostol, a uterine size < 12 weeks or > 15 weeks, unstable hemodynamic status and chock, signs of pelvic infection and/or sepsis. Main and secondary outcomes will be evaluated at follow up visit between 14-28 days by a obstetrician/gynecologist blinded to treatment allocation. A study cocordinating centre will be established at Mulago Hospital, Kampala. Preparations, permissions, and training will be ready by mid 2016. It is estimated that recruitment will start in 2016 and continue thorugh 2017. In 2018 data cleaning, analyses, and dissemination will be performed. Significance. We have shown that misoprostol is highly effective, acceptable and can safely be administered by midwives for first trimester PAC. There are several reasons to investigate the medical management option also for second trimester incomplete abortion including the difficulty in providing surgical methods in low resource settings due to scarcity of trained providers, sterile equipment and poor access to high level centres where surgical procedures are safely performed. Out-dated, unsafe methods such as sharp curettage are frequently used by untrained providers. In addition, in the setting of Ebola crisis where women are having abortions or miscarriages and there is reticence to have direct contact with infected women, an effective medical PAC regimen is paramount. In conjunction to the issue of limited trained providers, a misoprostol alone regimen for PAC would allow increased access. Results from this study can act as a springboard for future studies on midlevel provision of medical regimen for incomplete abortion management in the second trimester. The result will be used to inform policy makers and to revise training and service-delivery guidelines’ on a national level in Uganda. The long-term goal of this project is to provide evidence based information to develop strategies to increase women’s access to PAC at the lowest effective level in the health care s

Aktivitetslängd

Genomförandekanal

Bilateral

Ansvarig myndighet

Vetenskapsrådet

Aktivitets-ID

SE-0-SE-29-2015-03112-998-12182

Validation of immunological markers for use in screening of stomach cancer in low-income settings SEK 1 000 000

Medical Research

Beskrivning

Would research on cancer really be of benefit for the most underdeveloped countries? Yes, despite common belief, cancer is increasingly becoming a disease preferentially affecting the poor. In 2008, WHO estimated that 57 % of cancer cases and 65 % of cancer deaths occurred in less developed countries, and the magnitude of the problem in low-income countries is expected to increase during coming decades. Stomach cancer is a major health problem. It is the third most common cause of cancer death in the world, affecting around 700 000 people every year, the large majority (> 70 %) in low- and middle-income countries. In the countries defined as "least developed" or "other low-income", it is estimated that 17 350 stomach cancer deaths currently occur each year. As a comparison, the Ebola epidemic of West Africa in 2014 caused 9980 deaths. Stomach cancer mortality to a high degree affects the poorest people in all countries, regardless of whether these individuals reside in a country defined as a low-income country or not. Thus, large numbers of deaths by stomach cancer occur among the most poor populations of low-middle income developing countries of Latin America and Asia. The disease is most often caused by a chronic infection with the bacterium Helicobacter pylori, which is highly prevalent in less developed areas of the world. H. pylori infection is not a sufficient cause for stomach cancer, but other factors such as smoking and a poor diet add to the effects of the infection to increase risk of cancer development. Overall, around 2-3 % of infected individuals develop stomach cancer over the course of their life-time. An important barrier to improved health in the stomach cancer area is the fact that stomach cancer has very diffuse symptoms and therefore is diagnosed at a late stage. When the disease is discovered early, significantly increased long-term survival can be achieved by surgical treatment. A simple and low-cost method that can detect stomach cancer by screening in high-incidence countries would therefore be strongly beneficial. There are currently no biomarkers (identified biological markers) or screening tools available for stomach cancer. The current research project aims to establish and validate such a tool. The overall aim of the project is to develop a low-cost and minimally invasive screening test that can be used in low-income settings for identification of individuals affected by gastric cancer at an early stage of the disease. We propose to do this by detecting the natural biomarkers of the immune system: antibodies, using a low-cost lateral-flow assay. We will identify antibody signatures to H. pylori peptides that can be used to identify gastric cancer using blood or saliva samples. Our proposal rests on the fact that the immune response to H. pylori differs between individuals developing stomach cancer and individuals without cancer. The proposed project is an important part of an international collaboration between highly skilled research groups in Sweden, Nicaragua, Australia, Canada, Italy and USA, which are very well suited to conduct the outlined experiments due to long-standing expertise in mucosal immunology, immune assay development, H. pylori infection, oncology and cancer diagnosis. Specific aims of the project: 1. To identify a signature of Helicobacter pylori peptides that can be used as a screening tool to identify individuals with stomach cancer 2. To set up a low-cost test kit that allows use of this screening signature in low-income settings 3. To establish whether salivary samples can replace serum/plasma for screening If successful, our project will enable early detection and may thereby contribute to increased survival in stomach cancer disease in many of the poor countries around the world.

Aktivitetslängd

Genomförandekanal

Bilateral

Ansvarig myndighet

Vetenskapsrådet

Aktivitets-ID

SE-0-SE-29-2015-03509-998-12182

Combining metabolomics and genomics to develop new approaches for diagnosing and understanding bloodstream infections caused by antimicrobial resistan SEK 1 000 000

Medical Research

Beskrivning

Bloodstream infections (BSIs) caused by bacterial pathogens are a leading healthcare problem worldwide and a common cause of morbidity and mortality even in the countries with advanced healthcare systems. Treating the BSIs often demands intensive care measures including artificial ventilation and blood dialysis during such complications as multiple organ failure. The negative impact of BSI is especially pronounced in the low-income countries where the quality of the healthcare may be not capable of handling critically ill patients and/or the number of hospitals and their location is disproportional to demographic needs. Additionally, BSIs combined with antimicrobial resistance (AMR) constitute a particularly difficult problem to tackle. The infection develops quickly, the choice of effective therapies is limited and the process of selecting an appropriate treatment is slow as it involves the isolation of the etiologic agent. In case of multi-AMR of the pathogen, and lack of effective antimicrobials, medical professionals may have to fight the severe infection virtually unarmed with only empiric therapies. The grave scenario of returning to the pre-antimicrobial era is looming, and there are limited data regarding the epidemiology of AMR and BSI in low-income countries. Further, diagnostic methods for BSI are currently slow, ineffective and push healthcare personnel to administrate empirical treatment that may be not beneficial for the patient and may drive the AMR globally even further. Considering the urgent global challenges associated with AMR and BSIs, the aims of our study are: 1.To investigate the burden and clinical epidemiology of BSI in a tertiary hospital in Vietnam, a lower-middle income country with a population of 90.6 million. The identification and characterization of the bacteria causing BSI will be performed in the context of AMR (using whole genome sequencing). The influence of AMR and the type of infecting pathogen on the disease outcome will be analyzed. 2.To determine species specific and AMR metabolite signatures of bacteria causing BSIs. This will be performed in both blood samples from subjects with BSI and in bacterial cultures of AMR pathogens with distinct genetic backgrounds. Metabolomics data from clinical samples will be integrated with the corresponding data from genomic sequencing to produce reliable markers of AMR/BSI. 3.To develop a rapid diagnostic approach for the analysis of metabolite signatures of AMR/BSI in dry blood samples. Such samples can be quickly shipped from remote areas to the bigger health centers/laboratories and we aim to analyze the efficiency and the impact of such diagnostic strategy in low-income settings in Vietnam. To achieve the identified aims we will combine cutting-edge methods as next generation bacterial genome sequencing and highly sensitive metabolite analysis with clinical data and advanced bioinformatics. Statistical significance will be secured through recruiting of 7,000 participants in this study and we aim to sequence 1,000 clinically relevant bacterial genomes. This consortium is established for the project as partner Baker has extensive documented experience of microbiological/clinical investigations in Asian settings and applicant Antti is a field leader in metabolomics studies in infectious diseases. The applicants have a record of joint work and publication indicating successful communication and efficient collaboration of these groups. The expected impact of the study is highly significant. Within the four-year duration of the project we will have a detailed understanding of the epidemiology and genomics of AMR/BSI in a major hospital in Vietnam, a country heavily affected by AMR. The key factors for the propagation of AMR pathogens in Vietnam will be identified with the potential to extrapolate the results to other parts of Asia. The proposed approach for AMR/BSI testing by metabolite signatures will be designed, validated and may potentially d

Aktivitetslängd

Genomförandekanal

Bilateral

Ansvarig myndighet

Vetenskapsrådet

Aktivitets-ID

SE-0-SE-29-2015-03442-998-12182

ITP 300 SRHR International Training Program Sexual & Reproductive Health & Right - ITP 300 SRHR 2015 A (B1) AVSLUTAD SEK 875 080

Health personnel development

Beskrivning

International Training Programme (ITP): "Sexual and Reproductive Health and Rights"

Aktivitetslängd

Genomförandekanal

Bilateral

Ansvarig myndighet

Sida, Styrelsen för internationellt utvecklingssamarbete

Aktivitets-ID

SE-0-SE-6-5402001202-GGG-12281

JPO UNICEF 2014 USA Health JK SEK 562 316

Health policy and administrative management

Beskrivning

JPO UNICEF NY höst 2014

Aktivitetslängd

Genomförandekanal

Bilateral

Ansvarig myndighet

Sida, Styrelsen för internationellt utvecklingssamarbete

Aktivitets-ID

SE-0-SE-6-5412015401-GGG-12110

Minor contributions Soc 2014 - ISK WaterAid SEK 306 817

Health policy and administrative management

Beskrivning

Minor contribution 2014 for social sustainable development.Funds are allocated annually for minor studies, evaluations, audits, etc.

Aktivitetslängd

Genomförandekanal

Bilateral

Ansvarig myndighet

Sida, Styrelsen för internationellt utvecklingssamarbete

Aktivitets-ID

SE-0-SE-6-6105013207-GGG-12110

Agreement on Services, UKÄ, 2015 - 2017 - Agreement on Services, UKÄ, 2015 - SEK 45 651

Medical Research

Beskrivning

International Vaccine Institute, IVI aims at making vaccines available in LICs in order to reduce the burden of childhood diseases and thus <5 mortality. Sweden has since 2006 a representative in IVI's Board of Trustees and the Swedish Ministry of Foreign Affairs has given Sida the administrative responsibility to handle this.

Aktivitetslängd

Genomförandekanal

Bilateral

Ansvarig myndighet

Sida, Styrelsen för internationellt utvecklingssamarbete

Aktivitets-ID

SE-0-SE-6-5410016901-GGG-12182

UNICEF RMNCH Strategy and Coordination Team SEK -8 783

Health policy and administrative management

Beskrivning

Contribution to the "Strategy and Coordination Team" hosted by UNICEF in support of the Reproductive, Maternal, Newborn and Child Health (RMNCH) Trust Fund

Aktivitetslängd

Genomförandekanal

Bilateral

Ansvarig myndighet

Utrikesdepartementet

Aktivitets-ID

SE-0-SE-2-9999107001-GGG-12110

Network ReACt - Expansion CSO child SEK -30 442

Infectious disease control

Beskrivning

ReAct is a non-profit international network to improve the management of antibiotic resistance. ReAct's vision is that current and future generations will have access to effective prevention and treatment of bacterial infections as part of their right to health. ReAct aims to increase the global awareness of the negative effects of ABR, to increase the evidence generation, to promote innovation etc.

Aktivitetslängd

Genomförandekanal

Bilateral, core contributions to NGOs and other private bodies / PPPs

Ansvarig myndighet

Sida, Styrelsen för internationellt utvecklingssamarbete

Aktivitets-ID

SE-0-SE-6-5404004302-GGG-12250

Network ReACt SEK -38 651

Infectious disease control

Beskrivning

ReAct is a non-profit international network to improve the management of antibiotic resistance. ReAct's vision is that current and future generations will have access to effective prevention and treatment of bacterial infections as part of their right to health. ReAct aims to increase the global awareness of the negative effects of ABR, to increase the evidence generation, to promote innovation etc.

Aktivitetslängd

Genomförandekanal

Bilateral, core contributions to NGOs and other private bodies / PPPs

Ansvarig myndighet

Sida, Styrelsen för internationellt utvecklingssamarbete

Aktivitets-ID

SE-0-SE-6-5404004301-GGG-12250

Breastfeed Network/WABA - BF Network/WABA SEK -615 720

Basic nutrition

Beskrivning

Support to the network WABA, Ibfan Africa, Ibfan Gifa via WABA secretarit. The aim is to support and prevent exklusive breastfeeding and promotion of appropriate complementary feeding practice through networking, research and advocacy as well as follow up and assistance to governments in relation to relevant conventions; the rights of the child (CRC) and women´s convention (CEDAW) and others.

Aktivitetslängd

Genomförandekanal

Bilateral

Ansvarig myndighet

Sida, Styrelsen för internationellt utvecklingssamarbete

Aktivitets-ID

SE-0-SE-6-7230050701-GGG-12240

Year Värde (SEK) Värde (USD)
2020 SEK 29,6 m USD 3.1 m
2019 SEK 174 m USD 18.4 m
2018 SEK 249 m USD 28.7 m
2017 SEK 245 m USD 28.6 m
2016 SEK 160 m USD 18.7 m
2015 SEK 212 m USD 25.1 m
2014 SEK 692 m USD 101 m
2013 SEK 253 m USD 38.9 m
2012 SEK 248 m USD 36.6 m
2011 SEK 192 m USD 29.7 m
2010 SEK 424 m USD 58.9 m
2009 SEK 288 m USD 37.8 m
2008 SEK 378 m USD 56.6 m
2007 SEK 401 m USD 59.3 m
2006 SEK 367 m USD 49.8 m
2005 SEK 314 m USD 42.1 m
2004 SEK 234 m USD 31.9 m
2003 SEK 172 m USD 21.3 m
2002 SEK 149 m USD 15.4 m
2001 SEK 145 m USD 14.0 m
2000 SEK 125 m USD 13.6 m
1999 SEK 137 m USD 16.6 m
1998 SEK 124 m USD 15.7 m

Skapa inbäddningskod

  • Typ:

Förhandsgranskning

Inbäddningskod

Övrigt (bilateralt, ospecificerat)

Bilateralt bistånd som inte går att kategorisera till särskild geografisk plats och som inte inbegrips inom någon av de övriga biståndskategorierna.

Hälsa

Innefattar bland annat insatser inom hälso-och sjukvårdspolitik och förvaltning; utrustning och material för sjukvårdsinrättningar, psykiatrisk vård, mediciner samt bekämpning av sjukdomar och missbruk. Innefattar även grundläggande sjukvård och primärvård; hälsoupplysning, utbildning och kunskap till befolkning gällande folkhälsa till exempel inom nutrition och hygien. Utbildning av hälso- och sjukvårdspersonal samt bekämpning av smittsamma sjukdomar och icke-smittsamma sjukdomar.